Invasive aspergillosis in liver transplant recipients

Abstract

Background Liver transplantation is increasing worldwide with underlying pathologies dominated by metabolic and alcoholic diseases in developed countries. Methods We provide a narrative review of invasive aspergillosis (IA) in liver transplant (LT) recipients. We searched PubMed and Google Scholar for references without language and time restrictions. Results The incidence of IA in LT recipients is low (1.8%), while mortality is high (∼50%). It occurs mainly early (<3 months) after LT. Some risk factors have been identified before (corticosteroid, renal, and liver failure), during (massive transfusion and duration of surgical procedure), and after transplantation (intensive care unit stay, re‐transplantation, re‐operation). Diagnosis can be difficult and therefore requires full radiological and clinicobiological collaboration. Accurate identification of Aspergillus species is recommended due to the cryptic species, and susceptibility testing is crucial given the increasing resistance of Aspergillus fumigatus to azoles. It is recommended to reduce the dose of tacrolimus (50%) and to closely monitor the trough level when introducing voriconazole, isavuconazole, and posaconazole. Surgery should be discussed on a case‐by‐case basis. Antifungal prophylaxis is recommended in high‐risk patients. Environmental preventative measures should be implemented to prevent outbreaks of nosocomial aspergillosis in LT recipient units. Conclusion IA remains a very serious disease in LT patients and should be promptly sought and, if possible, prevented by clinicians when risk factors are identified.

Increased Risk of Invasive Aspergillosis in Immunocompromised Patients With Persistent SARS-CoV-2 Viral Shedding &gt;8 Weeks, Retrospective Case-control Study

“…Invasive aspergillosis can occur in the setting of viral infections because of virus-induced alteration of the respiratory epithelium and modification of immune responses, a phenomenon accentuated by mechanical ventilation and corticosteroid therapy in the ICU [ 35 , 36 ]. In immunocompromised patients not hospitalized in the ICU, this mechanism is supported by the absence of cellular and humoral responses against both agents, virus and fungus [ 37 ]. Nevertheless, the exact pathophysiology leading to invasive aspergillosis in non-ICU immunocompromised patients infected with SARS-CoV-2 has not been clearly identified.…”

Atypical imaging patterns during lung invasive mould diseases: lessons for clinicians

“…SOT recipients are a well-known population at risk for IMDs, mainly regarding Aspergillus ssp. Although the overall IPA incidence in this setting remains below 10%, at least in non-lung transplanted patients [ 71 , 72 ], the mortality rate is still high, mainly in liver transplant recipients [ 71 , 73 ]. Regarding pulmonary IMDs, SOT recipients are likely to show peri-bronchial consolidations or GGOs and less likely macronodules, mass-like consolidations, halo signs and air crescent signs [ 74 ].…”

Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients

“…Lung transplant recipients have a higher risk for developing invasive aspergillosis (IA) (tracheobronchitis and pulmonary aspergillosis [IPA]) due to specific characteristics related to this transplant: higher rate of pre-transplant colonization, airway ischemia, impaired ciliary function, blunted cough reflex, and denervation injury [3]. Other known risk factors for IMD are post-transplantation renal replacement treatment, cytomegalovirus infection, treatment for acute rejection, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and liver re-transplantation or transplantation due to fulminant hepatic failure [4,5]. The morbidity and mortality associated with these infections is extremely high.…”